NCT04758130: GRIT

Getting Global Rare Disease Insights Through Technology Study

Status unknown NA Last updated 8 April 2021

What this trial tests

NA trial testing Zamplo Digital Health Platform in Metabolic Disease in 150 participants. Status unknown.

Timeline

7 August 2020

Primary endpoint
15 May 2021

30 November 2021

Quick facts

Lead sponsor	M.A.G.I.C. Clinic LTD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	150
Start date	7 August 2020
Primary completion	15 May 2021
Estimated completion	30 November 2021
Sites	1 location across Canada

Drugs / interventions tested

• Zamplo Digital Health Platform

Conditions studied

• Metabolic Disease — all drugs for Metabolic Disease →
• Fabry Disease — all drugs for Fabry Disease →
• Gaucher Disease — all drugs for Gaucher Disease →
• Pompe Disease — all drugs for Pompe Disease →

Sponsor

M.A.G.I.C. Clinic LTD

Who can join

18 and older, any sex, with Metabolic Disease or Fabry Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project is a randomized controlled trial to use a mobile health journal, called Zamplo (formerly known as MyHealthJournal or ZoeInsights), to record patient reported outcomes (PROM) in patients with metabolic disorders.

The objective of the study is to assess the feasibility, acceptability and potential effectiveness of the Zamplo.

The primary hypothesis is as follows:

The Zamplo platform will significantly increase patient activation at 6 months post-baseline, defined as an individual's knowledge, skill, and confidence for managing their health and health care.

The primary outcome is as follows:

Patient activation following the use of Zamplo will serve as the primary outcome of interest and will be measured by the Patient Activation Measure (PAM) 13. The PAM 13 shows the degree of the patient's ability to manage their health with confidence by providing a total patient activation score.

Brief Background:

This project is a randomized controlled trial to use a mobile health journal, called Zamplo, to record patient reported outcomes (PROM) in patients with metabolic disorders.

Zamplo is a software as a service (SaaS) digital platform on both iOS and Android platforms that allows real-time entry of patient symptoms and response to medications. It provides the patients with an interface to see their progress, store questions that they will ask at the next clinic visit, record their health data and use their data to engage in their health outcomes. MAGIC Clinic Ltd., which is the largest clinic in Alberta that manages metabolic disorders such as Fabry disease, Pompe disease, and Gaucher disease, will provide access to Zamplo to patients free-of-charge to evaluate its utility in managing the symptoms of their disease.

Brief Study Design:

The study is a two-armed randomized controlled design with 1:1 allocation to treatment (Zamplo app group) or control (usual care) arms, with assessments at four time points: baseline, 1 month, 3 months (primary outcome), 6 months and 12 months follow-up post-baseline. This is an open-label trial.

The investigators intend to recruit 150 participants in this study, with 75 of them being controls.

Inclusion Criteria:

Adult patients with a diagnosis of metabolic disease Access to a smartphone with data connection Willingness to devote 10-15 mins of time in a day to log medications and notes Able to speak and write English sufficiently to complete questionnaires.

Exclusion Criteria:

Insufficient cognitive function to participate in the study The use of any electronic application requires some competency with the software on a cellphone, downloading the application and entering the data. Some patients who are elderly may not be familiar with this technology and would be excluded.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.